Literature DB >> 12441083

Evolution of total and integrated HIV-1 DNA and change in DNA sequences in patients with sustained plasma virus suppression.

Jacques Izopet1, Michèle Cazabat, Christophe Pasquier, Karine Sandres-Sauné, Eric Bonnet, Bruno Marchou, Patrice Massip, Jacqueline Puel.   

Abstract

Blood samples from patients with plasma HIV-1 RNA <20 copies/ml for more than 2 years were studied. Significant decreases in total and integrated HIV-1 DNA were observed during the first 15 months of suppressive therapy before the concentrations became stable. Clonal analysis of HIV-1 pol demonstrated that the proportions of resistance mutations in DNA sequences after 2 years were lower than those in baseline DNA and RNA sequences. The changes in the clonal composition of HIV-1 env populations in three patients with evidence of changes in HIV-1 pol populations indicated a shift from predominantly R5-like viruses to predominantly X4-like viruses in two patients and the persistence of predominantly X4-like viruses in the third. Our analyses indicate the reemergence of ancestral sequences from long-lived cells or the residual production of wild-type virus from anatomic sites with limited access to antiretroviral drugs and the preferential infection of cells expressing CXCR4.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441083     DOI: 10.1006/viro.2002.1621

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy.

Authors:  Rami Kantor; Robert W Shafer; Stephen Follansbee; Jonathan Taylor; David Shilane; Leo Hurley; Dong-Phuong Nguyen; David Katzenstein; W Jeffrey Fessel
Journal:  AIDS       Date:  2004-07-23       Impact factor: 4.177

2.  Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs.

Authors:  Luis M Agosto; Megan K Liszewski; Angela Mexas; Erin Graf; Matthew Pace; Jianqing J Yu; Avinash Bhandoola; Una O'Doherty
Journal:  Virology       Date:  2011-01-05       Impact factor: 3.616

3.  Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.

Authors:  Adam MacNeil; Abdoulaye Dieng Sarr; Jean-Louis Sankalé; Seema Thakore Meloni; Souleymane Mboup; Phyllis Kanki
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

4.  Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.

Authors:  Lisa M Frenkel; Yang Wang; Gerald H Learn; Jennifer L McKernan; Giovanina M Ellis; Kathleen M Mohan; Sarah E Holte; Shannon M De Vange; Diane M Pawluk; Ann J Melvin; Paul F Lewis; Laura M Heath; Ingrid A Beck; Madhumita Mahalanabis; Wilscott E Naugler; Nicole H Tobin; James I Mullins
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.

Authors:  J M Carr; K M Cheney; C Coolen; A Davis; D Shaw; W Ferguson; G Chang; G Higgins; C Burrell; P Li
Journal:  J Clin Microbiol       Date:  2007-02-21       Impact factor: 5.948

6.  A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients.

Authors:  Jianqing J Yu; Te Lang Wu; Megan K Liszewski; Jihong Dai; William J Swiggard; Clifford Baytop; Ian Frank; Bruce L Levine; Wei Yang; Theodore Theodosopoulos; Una O'Doherty
Journal:  Virology       Date:  2008-07-22       Impact factor: 3.616

Review 7.  Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR.

Authors:  Megan K Liszewski; Jianqing J Yu; Una O'Doherty
Journal:  Methods       Date:  2009-02-03       Impact factor: 3.608

8.  Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapy.

Authors:  Joseph P Casazza; Michael R Betts; Brenna J Hill; Jason M Brenchley; David A Price; Daniel C Douek; Richard A Koup
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

9.  Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART.

Authors:  Erin H Graf; Angela M Mexas; Jianqing J Yu; Farida Shaheen; Megan K Liszewski; Michele Di Mascio; Stephen A Migueles; Mark Connors; Una O'Doherty
Journal:  PLoS Pathog       Date:  2011-02-24       Impact factor: 6.823

10.  Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells.

Authors:  Hendrik Streeck; Zabrina L Brumme; Michael Anastario; Kristin W Cohen; Jonathan S Jolin; Angela Meier; Chanson J Brumme; Eric S Rosenberg; Galit Alter; Todd M Allen; Bruce D Walker; Marcus Altfeld
Journal:  PLoS Med       Date:  2008-05-06       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.